15 Jan2015
Australian clinical research company expands operation in Hong Kong
Hong Kong (HKSAR) – Sydney-based Novotech today (January 15) announced that it has expanded its Hong Kong operation into a permanent office with more staff to meet the increasing demand in the pharmaceutical market for clinical research.

Despite the advent of intrapartum antibiotic prophylaxis (IAP) and ongoing attempts to identify more accurate diagnostic tools, neonatal sepsis or bacteremia remains a common and potentially deadly occurrence, particularly in very-low-birth-weight (VLBW, <1500 g) babies. Sepsis causes up to 26% of all 